2 recruiting, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow iadademstat: new trials by email Literature Review of iadademstat trials Research Report on iadademstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-11-16 |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2025-04-08 | 2026-11-16 |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma | Phase 2 | Terminated | Fox Chase Cancer Center | 20 | 2022-12-21 | 2025-07-30 |
Carcinoma, Neuroendocrine (1) · Lung Neoplasms (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Small Cell Lung Carcinoma (1) · Thrombocythemia, Essential (1)
National Cancer Institute (NCI) (2) · Fox Chase Cancer Center (1)
United States (3)
Anand A Patel (1) · Charles M Rudin (1) · Namrata Vijavergia (1)
UM1CA186691 (1), UM1CA186717 (1)